enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company’s 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene’s Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson.

“We are pleased to welcome Paul and Wouter to our Board of Directors. Their breadth of biopharma industry experience across research, corporate management and finance equips them well to serve as Board members of enGene, particularly as we look to the potential expansion of our pipeline across additional urological indications and move towards our planned BLA filing for EG-70 in the first quarter of 2026,” said Jason Hanson, Chief Executive Officer of enGene.

“enGene’s non-viral DDX platform holds great promise in realizing the Company’s vision of mainstreaming genetic medicines, and I believe the design of EG-70 for ease of use makes it uniquely well-matched to the needs of community urologists caring for patients with NMIBC,” remarked Mr. Hastings. “The Company is well-positioned for success, and I look forward to working with the management team to execute its vision.”

Mr. Joustra said, “I’m thrilled to join enGene’s Board of Directors. There continues to be a profound unmet need in NMIBC, and I believe EG-70’s product profile stands out and supports a potential future role as the intravesical therapy of first choice for community and high-volume urology clinics across the country. The Company has laid out a compelling strategic plan and is looking forward to several exciting milestones, including the planned announcement of interim data from its pivotal Phase 2 Legend study mid-year as well as the planned expansion of the EG-70 program into new indications.”

Mr. Hastings has served as the President, Chief Executive Officer, and a member of the board of directors of Nkarta, Inc. (NASDAQ: NKTX) since February 2018. Prior to that, he served as President, Chief Executive Officer, and Director of the publicly traded, clinical-stage biopharmaceutical company OncoMed Pharmaceuticals, Inc. from January 2006 until January 2018. In August 2013, he was elected Chairman of the board of directors of OncoMed and served in that role until January 2018. Prior to joining OncoMed, Mr. Hastings was President, Chief Executive Officer, and Director of QLT, Inc., a publicly traded biotechnology company dedicated to the development and commercialization of innovative ocular products, from February 2002 to September 2006. From 2000 to 2002, Mr. Hastings served as President, Chief Executive Officer, and Director of Axys Pharmaceuticals, Inc., which was acquired by Celera Corporation in 2001. Mr. Hastings was also previously the President of Chiron Biopharmaceuticals, a division of Chiron Corporation, President and Chief Executive Officer of LXR Biotechnology, and he held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics.